ID | 67534 |
フルテキストURL | |
著者 |
Iwasaki, Keiichiro
Department of Cardiovascular Medicine, Okayama University Institute of Academic and Research, Medicine, Dentistry and Pharmaceutical Sciences
Miyoshi, Toru
Department of Cardiovascular Medicine, Okayama University Institute of Academic and Research, Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
Urabe, Chikara
Department of Cardiovascular Medicine, Okayama University Institute of Academic and Research, Medicine, Dentistry and Pharmaceutical Sciences
Sakuragi, Satoru
Department of Cardiovascular Medicine, Iwakuni Clinical Center
Kawai, Yusuke
Department of Cardiovascular Medicine, Okayama City Hospital
Fuke, Soichiro
Department of Cardiovascular Medicine, Japanese Red Cross Okayama Hospital
Doi, Masayuki
Department of Cardiology, Kagawa Prefectural Central Hospital
Takaishi, Atsushi
Department of Cardiology, Mitoyo General Hospital
Oka, Takefumi
Department of Cardiology, Tsuyama Chuo Hospital
Tokunaga, Naoto
Department of Cardiology, Ibara City Hospital
Ito, Hiroshi
Department of General Internal Medicine 3, Kawasaki Medical School
Kaken ID
|
抄録 | Background/Objectives: Indoxyl sulfate, a uremic toxin, is associated with mortality and cardiovascular events in patients with chronic kidney disease (CKD). This study aimed to evaluate the prognostic implications of serum indoxyl sulfate levels in patients with heart failure and CKD. Methods and Results: This was a prospective multicenter observational study. Overall, 300 patients with chronic heart failure with a previous history of hospitalization and an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or less (CKD stage G3b to G5) without dialysis were analyzed. The primary outcome assessed in a time-to-event analysis from the measurement of indoxyl sulfate was a composite of all-cause death, hospitalization for heart failure, nonfatal myocardial infarction, and nonfatal stroke. Clinical events were followed-up to one year after indoxyl sulfate measurement. The median patient age was 75 years, and 57% of the patients were men. We divided the cohort into low and high indoxyl sulfate categories according to a median value of 9.63 mg/mL. The primary outcome occurred in 27 of 150 patients (18.0%) in the low indoxyl sulfate group and 27 of 150 patients (18.0%) in the high indoxyl sulfate group (hazard ratio, 1.00; 95% confidence interval, 0.58 to 1.70, p = 0.99). In the post hoc exploratory analyses, the results were consistent across age, sex, body mass index, left ventricular ejection fraction, eGFR, and N-terminal pro b-type natriuretic peptide. Conclusions: Among heart failure patients with CKD stages G3b to 5G, serum indoxyl sulfate concentrations were not significantly associated with the subsequent occurrence of cardiovascular events.
|
キーワード | heart failure
chronic kidney disease
indoxyl sulfate
|
発行日 | 2024-07-26
|
出版物タイトル |
Journal of Clinical Medicine
|
巻 | 13巻
|
号 | 15号
|
出版者 | MDPI
|
開始ページ | 4384
|
ISSN | 2077-0383
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2024 by the authors.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.3390/jcm13154384
|
ライセンス | https://creativecommons.org/licenses/by/4.0/
|
Citation | Iwasaki, K.; Miyoshi, T.; Urabe, C.; Sakuragi, S.; Kawai, Y.; Fuke, S.; Doi, M.; Takaishi, A.; Oka, T.; Tokunaga, N.; et al. Impact of Serum Indoxyl Sulfate on One-Year Adverse Events in Chronic Kidney Disease Patients with Heart Failure. J. Clin. Med. 2024, 13, 4384. https://doi.org/10.3390/jcm13154384
|
助成機関名 |
KUREHA Corporation
|